

## IL12R $\beta$ 1 defect presenting with massive intra-abdominal lymphadenopathy due to *Mycobacterium intracellulare* infection

Eda KepenekliKadayifci,<sup>1</sup> Ayşe Karaaslan,<sup>1</sup> Serkan Atıcı,<sup>1</sup> Gülşen Akkoç,<sup>1</sup> Safa Barış,<sup>2</sup> Nurhayat Yakut,<sup>1</sup> Sevliya Öcal Demir,<sup>1</sup> Orhan Kaya Köksalan,<sup>3</sup> Ahmet Soysal,<sup>1</sup> Caroline Deswarte,<sup>4,5</sup> Jacinta Bustamante,<sup>4,5,6,7,8</sup> Jean-Laurent Casanova,<sup>4,5,6,8,9</sup> Mustafa Bakır<sup>1</sup>

### Abstract

Infections due to non-tuberculous mycobacteria species are problematic for immunodeficient individuals. Mendelian susceptibility to mycobacterial diseases (MSMD) defines a group of genetic defects affecting cellular interactions and the interferon (IFN)- $\gamma$  pathway. Patients with MSMD may present with a disseminated infection resulting from the Bacillus Calmette-Guerin vaccine, *Mycobacterium tuberculosis* complex, environmental nontuberculous mycobacteria or Salmonella species. Atypical mycobacterial infections and deficient granuloma or giant cell formation are important indicators for MSMD, especially in patients with a family history of parental consanguineous marriage.

Herein we report the case of a boy with an IL-12R $\beta$ 1 defect who presented with massive intraabdominal lymphadenopathy due to *Mycobacterium intracellulare* infection. The patient was born to consanguineous parents, both heterozygous for the IL-12R $\beta$ 1 defect mutation. Debulking surgery was planned in order to decrease the abdominal mass, but could not be performed due to a high risk of fatal outcomes. He has been receiving linezolid, levofloxacin, azithromycin, rifabutin and IFN- $\gamma$  therapy for the past 14 months. At follow-up, the patient showed significant clinical improvement and weight gain.

**Keywords:** Atypical mycobacteria; Child; Immune deficiency; *Mycobacterium intracellulare*; IL-12R $\beta$ 1 defect

### From:

<sup>1</sup> Marmara University School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Diseases, Istanbul, Turkey

<sup>2</sup> Marmara University School of Medicine, Department of Pediatrics, Division of Pediatric Allergy and Immunology, Istanbul, Turkey

<sup>3</sup> İstanbul University, İstanbul School of Medicine, Experimental Medicine Research Institute- Molecular Epidemiology of Tuberculosis Laboratory, İstanbul, Turkey

<sup>4</sup> Paris Descartes University, Imagine Institute, Paris, France

<sup>5</sup> Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France

<sup>6</sup> St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA

<sup>7</sup> Center for the Study of Primary Immunodeficiencies, AP-HP, Necker Hospital for Sick Children, Paris, France

<sup>8</sup> Howard Hughes Medical Institute, New York, USA

<sup>9</sup> Pediatric Hematology-Immunology Unit, Necker Hospital for Sick Children, Paris, France

### Corresponding author:

Ahmet Soysal

Marmara University School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Diseases, Istanbul, Turkey

E-mail: asoyal@marmara.edu.tr

### Introduction

Nontuberculous mycobacteria (NTM) species, otherwise known as atypical mycobacteria, are defined as species of the *Mycobacterium* genus excluding *Mycobacterium tuberculosis* complex and *M. leprae*. NTM are ubiquitous in the environment, and while they can cause disease in immunocompetent individuals, NTM infection is particularly problematic for immunodeficient individuals or those with a chronic lung disease.<sup>1,2</sup> The most common forms of NTM infection in children involve the cervical lymphadenitis, skin and soft tissue, and can cause disseminated disease in immunocompromised patients.<sup>1</sup>

Interactions between macrophages, T cells, natural killer (NK) cells and the interferon (IFN)- $\gamma$  pathway are critical for

the control of mycobacterial infections.<sup>3-5</sup> Mendelian susceptibility to mycobacterial diseases (MSMD) are defined by a group of genetic defects involving cellular interactions and the IFN- $\gamma$  pathway, important for the control of intracellular infections.<sup>6</sup> Patients with MSMD typically present with disseminated infection due to the Bacillus Calmette-Guerin (BCG) vaccine or infection with environmental NTM species. Disease severity and age of onset depends on both the part of the IFN- $\gamma$  pathway affected and the severity of the genetic defect.<sup>5-8</sup> Consanguineous marriage is a risk factor for a subgroup of MSMD patients due to its autosomal recessive (AR) inheritance pattern.

Herein we present a case report of a 3-year-old boy with an

*IL-12Rβ1* defect who presented with massive intraabdominal lymphadenopathy due to *Mycobacterium intracellulare* infection.

### Case report

A 3-year-old boy, born to consanguineous Azerbaijani parents, was admitted to a hospital in Azerbaijan with abdominal distention, fever, night sweats, anorexia and weight loss. Multiple intra-abdominal lymphadenopathies were detected by ultrasonography. The patient was transferred for treatment in Iran with the presumed diagnosis of Histiocytosis X, after histopathological examination of the abdominal lymph nodes. Chemotherapy for Histiocytosis X was given for 2 months. He was then transferred to Turkey due to poor response to chemotherapy. The physical examination revealed a fever (39°C), abdominal distention and cachexia. Laboratory evaluation of the patient was as follows: hemoglobin 11.6 g/dL, white

blood cell count  $15 \times 10^3/\mu\text{L}$ , absolute neutrophil count  $10.7 \times 10^3/\mu\text{L}$ , absolute lymphocyte count  $2.5 \times 10^3/\mu\text{L}$ , erythrocyte sedimentation rate (ESR) 95 mm/hour, C-reactive protein 112 g/dL (range 0–5 g/dL). Liver transaminases were found to be within the normal range. Multiple massive diffuse intraabdominal lymph nodes were found during his abdominal ultrasonography, the largest of which was  $4 \times 5$  cm in size. The positron emission computerized tomography (PET-CT) showed multiple, intensely hypermetabolic lymph nodes at cervical, mediastinal and abdominal sites, consistent with lymphoproliferative disorders (**Figure 1**). To strengthen the diagnosis, another biopsy was taken from the mesenteric lymph nodes, and this second biopsy showed multiple irregular histiocytes that were filled with acid-fast bacilli (AFB) (**Figure 2**). The thorax CT scan showed pneumonic consolidation on the lower lobe of the left lung and paratracheal lymphadenomegaly ( $1.2 \times 0.8$  cm). Direct microscopy for AFB was negative, in addition to negative results for a PCR analysis of *M. tuberculosis*





Figure 1. PET-CT images showing multiple intense hypermetabolic cervical and abdominal lymphadenopathies.



**Figure 2. Multiple irregular histiocytes full with acid-fast bacilli in mesenteric lymph node specimens**

in the gastric lavage fluid, anti-HIV serology and the T-spot-TB test. Isoniazid, rifampicin, ethambutol, pyrazinamid (HRZE) and chlarythromycin therapies were given for 2 months. The anti-mycobacterial combination regimen was changed to linezolid, levofloxacin, azithromycin, rifabutin and amikacin when the lymph node mycobacterial PCR analysis revealed *M. intracellulare* infection. His lymphocyte subset (T, B and NK cells) analysis, immunoglobulin level and dihydrorhodamine tests were normal, excluding the most frequent classical primary immunodeficiencies. Debulking surgery to decrease the abdominal mass could not be performed due to a high possibility of fatal outcomes. His lymph node biopsy revealed histiocyte irregularities and the absence of an organized giant cell structure, indicating defects in the IFN- $\gamma$  pathway. A homozygous mutation in the *IL12RB1* gene (c.1073G>C), p.Trp358X, was detected by the molecular genetic analysis, which was performed by a research laboratory in France. Both parents were also found to be heterozygous for this mutation. In addition, staining of the IL-12R $\beta$ 1 protein in the patient's T lymphocytes was negative.

IFN- $\gamma$  therapy (0.05 mg/day, subcutaneously three times a week) began following the MSMD diagnosis. Fever and chills were observed in the boy during IFN therapy. The diameter of the abdominal lymph nodes and the ESR was found to have

decreased after 6 months of antimicrobial therapy. Amikacin therapy was discontinued due to parental concerns about its autotoxic side effects. The patient has been receiving linezolid, levofloxacin, azithromycin and rifabutin for the past 14 months. The most recent laboratory evaluation of the patient was as follows: hemoglobin 12.6 g/dL, white blood cell count  $6 \times 10^3/\mu\text{L}$ , ESR 8 mm/hour, C-reactive protein 4 g/dL (range 0–5 g/dL). The size of the largest abdominal lymph node has decreased from  $4 \times 5$  cm to  $1.5 \times 1$  cm. The clinical condition of the patient has improved substantially, with weight gain and nofever. Furthermore, no persistent infection was present at follow-up. The two healthy siblings of the patient were invited for genetic analysis and genetic counseling.

## Discussion

*Mycobacterium avium-intracellulare* complex (MAC) is ubiquitous in soil and water. *Mycobacterium avium* complex and MAC include two mycobacterial species, *M. avium* and *M. intracellulare*. These two species cannot be differentiated based on traditional physical and biochemical tests. While *M. avium* usually causes disseminated disease, *M. intracellulare* acts as a respiratory pathogen.<sup>19</sup> Cervical lymphadenitis resulting from MAC can be observed in immunocompetent children. Patients should be screened for HIV infection if they present with

abdominal or mediastinal lymphadenitis due to MAC.<sup>10</sup> Most first-line antituberculosis drugs have poor activity against MAC, however, macrolide drugs have demonstrated *in vitro* and clinical activities against MAC.<sup>1,11</sup>

Interleukin (IL)-12 and IFN- $\gamma$  are responsible for providing an activation loop between macrophages and T cells/NK cells in order to amplify the immune response against mycobacteria, in addition to the formation of granuloma or giant cells.<sup>5,7</sup> To date, 18 different genetic disorders have been associated with a mutation in the IFN- $\gamma$  pathway, most of which have an AR inheritance pattern. The genetic disorders underlying MSMD can be differentiated based on their mode of transmission, expression of the mutant protein or its function.<sup>4,6-8</sup> Clinical phenotypes of these diseases are heterogeneous, ranging from localized to severe infection, and dissemination can cause potentially fatal infections.<sup>5</sup>

In the literature, only few case reports have described patients with MSMD and intra-abdominal mycobacterial infections. Özbek et al. reported the case of an 11-year-old girl who presented with disseminated tuberculosis and an intra-abdominal abscess, who was found to have an *IL12R $\beta$ 1* defect. She was treated with rifampin, clarithromycin, ciprofloxacin and streptomycin.<sup>12</sup> Law et al. reported a 13-year-old girl with defective mitogen-induced IL-12 production, who developed intestinal tuberculosis with wide dissemination, including the lungs and urinary tract. Similar to our case, histological examination of the intestinal tissue revealed several ill-formed granulomas with numerous AFB, however, caseous necrosis was absent. The patient described by Law et al. remained well following 18 months of anti-tuberculous therapy, which included isoniazid, pyrazinamide, ethambutol, amikacin, levofloxacin and moxifloxacin.<sup>13</sup>

The patient reported here had a family history of consanguineous marriage, and presented with NTM infection, isolated from the abdominal lymph nodes, in addition to the existence of numerous AFBs, irregular histiocytes, and an absence of well-organized giant cell structures in lymph node specimens, which lead to the MSMD diagnosis. Therefore, genetic analysis was performed, and a mutation in the *IL12R $\beta$ 1* gene was identified, conferring complete IL-12R $\beta$ 1 deficiency, characterized by no expression of the receptor. Similar to the aforementioned case reports, our patient responded well to anti-tuberculous therapy including both first- and second-line drugs with high bactericidal activity. The patient was also started on IFN- $\gamma$  therapy, which is recommended for patients with an IL-12R $\beta$ 1 deficiency.

Patients with an IL-12R $\beta$ 1 deficiency usually have relatively mild clinical symptoms and good prognosis,<sup>14</sup> and hematopoietic stem cell transplantation is not required. Management consists of anti-mycobacterial drugs and recombinant IFN- $\gamma$  treatment. In the literature, children with an IL-12R $\beta$ 1 deficiency have been reported to present with nocardiosis, recurrent salmonellosis, cryptococcal osteomyelitis, multifocal tuberculous osteomyelitis, BCG-osis and disseminated *M. tuberculosis* infection.<sup>15-19</sup> Differential MSMD diagnosis requires the exclusion of other granulomatous (infectious or noninfectious) inflammation according to the clinical and biological manifestations. Other diseases can be misdiagnosed, such as Langerhans cell histiocytosis or bone metastasis.<sup>20</sup> Therefore,

a detailed summary of the clinical and histological features should facilitate accurate diagnosis and treatment in order to avoid unnecessary cytotoxic chemotherapy. In our patient, the therapy was altered to a different anti-mycobacterial regimen following MAC isolation, which included a macrolide drug. The therapy also included second-line parenteral anti-tuberculosis drugs with high bactericidal activity (linezolid, amikacin and levofloxacin), in addition to rifabutin and IFN- $\gamma$ , due to the patient's poor clinical condition.

Atypical mycobacterial infections and deficient granuloma or giant-cell formation are important indicators of MSMD, especially if there is a family history of consanguineous marriage of parents.

### Conflict of interest

All authors declare no conflicts of interest.

### Acknowledgements

None.

### References

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med.* 2007;175:367-416.
2. Boisson-Dupuis S, Bustamante J, El-Baghdadi J, Camcioglu Y, Parvaneh N, El Azbaoui S, et al. Inherited and acquired immunodeficiencies underlying tuberculosis in childhood. *Immunol Rev.* 2015;264:103-20.
3. Safdar A, White DA, Stover D, Armstrong D, Murray HW. Profound interferon gamma deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. *Am J Med.* 2002;113:756-9.
4. Vankayalapati R, Wize B, Samten B, Griffith DE, Shams H, Galland MR, et al. Cytokine profiles in immunocompetent persons infected with *Mycobacterium avium* complex. *J Infect Dis.* 2001;183:478-84.
5. Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. *J Allergy Clin Immunol.* 2008;122:1043-51.
6. Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN- $\gamma$  immunity. *Semin Immunol.* 2014;26:454-70.
7. Darleguy A, Bost-Brua C, Pagnier A, Plantaz D, Piolat C, Nuges F, et al. Mendelian susceptibility to mycobacterial disease: a case report of disseminated infection due to *Mycobacterium avium*. *Arch Pediatr.* 2013;20:758-61.
8. Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, Baretto R, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. *Lancet.* 2004;364:2113-21.
9. Horsburgh CR Jr. Epidemiology of *Mycobacterium avium* complex. In: Korvick JA, Benson CA, editors. *Mycobacterium avium* complex infection: progress in research and treatment. New York: Marcel Dekker; 1996. p. 1-22.
10. Hassell M, French MA. *Mycobacterium avium* infection and immune restoration disease after highly active antiretroviral therapy in a patient with HIV and normal CD4 counts. *Eur J Clin Microbiol Infect Dis.* 2001;20:889-91.
11. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin in the treatment of *Mycobacterium avium* lung infections in patients without AIDS. *Chest.* 1995;107:1035-40.
12. Özbek N, Fieschi C, Yilmaz BT, de Beaucoudrey L, Demirhan B, Feinberg J, et al. Interleukin-12 Receptor  $\beta$ 1 Chain Deficiency in a Child with Disseminated Tuberculosis. *Clin Infect Dis.* 2005;40:e55-8.
13. Law ST, Chiu SC, Li KK. Intestinal tuberculosis complicated with perforation during anti-tuberculous treatment in a 13-year-old girl with defective mitogen-induced IL-12 production. *J Microbiol Immunol Infect.* 2014;47:441-6.

14. de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al. Revisiting human IL-12R $\beta$ 1 deficiency: a survey of 141 patients from 30 countries. *Medicine*. 2010;89:381-402.
15. Luangwedchakarn V, Jirapongsaranuruk O, Niemela JE, Thepthai C, Chokephaibulkit K, Sukpanichnant S, et al. A Novel Mutation of the IL12RB1 Gene in a Child with Nocardiosis, Recurrent Salmonellosis and Neurofibromatosis Type I: First Case Report from Thailand. *Asian Pac J Allergy Immunol*. 2009;27:161-5.
16. Jirapongsananuruk O, Luangwedchakarn V, Niemela JE, Pacharn P, Visitsunthorn N, Thepthai C, et al. Cryptococcal osteomyelitis in a child with a novel compound mutation of the IL12RB1 gene. *Asian Pac J Allergy Immunol*. 2012;30:79-82.
17. Nampoothiri S, Singh S, Nampoothiri KNP, Boisson-Dupuis S, Abel L, Casanova JL. Multifocal Tuberculous Osteomyelitis: Possible Inherited Interferon Gamma Axis Defect. *Indian J Pediatr*. 2013;80:505-8.
18. Sarrafzadeh SA, Mahloojirad M, Nourizadeh M, Casanova JL, Pourpak Z, Bustamante J, et al. Mendelian Susceptibility to Mycobacterial Disease due to IL-12R $\beta$ 1 Deficiency in Three Iranian Children. *Iran J Public Health*. 2016;45:370-5.
19. Schepers K, Schandené L, Bustamante J, Van Vooren JP, de Suremain M, Casanova JL, et al. IL-12R $\beta$ 1 Deficiency and Disseminated Mycobacterium tuberculosis Disease. *J Clin Immunol*. 2013;33:1285-8.
20. Edgar JD, Smyth AE, Pritchard J, Lammas D, Jouanguy E, Hagué R, et al. Interferon-gamma receptor deficiency mimicking Langerhans' cell histiocytosis. *J Pediatr*. 2001;139:600-3.